Adaptimmune Therapeutics (ADAPY) AI Stock Analysis

• Market Cap: $9.28M
• Dividend Yield: N/A
• Average Volume (3M): 50.65M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.75
• Revenue Growth: -53.61%
• EPS Growth: -93.14%
• Country: US
• Employees: 506
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 265,051,600
• 10 Day Avg. Volume: 4,539,686
• 30 Day Avg. Volume: 50,649,310
• PEG Ratio: 0.04
• Price to Book (P/B): 11.47
• Price to Sales (P/S): 0.76
• P/FCF Ratio: -1.79
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $0.03 ▲(13.33% Upside)

The score is primarily weighed down by weak financial performance, including steep revenue decline, ongoing losses, negative cash flows, and negative equity. Technicals also remain bearish with price below all key moving averages, though oversold indicators suggest potential near-term stabilization. Valuation provides limited support due to negative earnings and no dividend yield data.

Positive Factors

High gross margins

A very high gross margin indicates the company’s therapies have low variable production costs and attractive unit economics. If Adaptimmune can scale clinical success and commercialize SPEAR therapies, these margins support strong long-term profitability even as fixed R&D and SG&A scale.

Proprietary SPEAR platform

Owning a differentiated SPEAR T‑cell platform targeted at solid tumors gives Adaptimmune durable competitive advantage via specialized IP, know‑how and clinical differentiation. Platform leverage can support multiple programs, spreading R&D investments across indications.

Partnership-driven revenue model

A business model centered on collaborations delivers non-dilutive funding via upfronts, milestones and potential royalties, extending R&D runway and validating programs through partner commitments. This reduces sole reliance on product sales during commercialization ramp.

Negative Factors

Sharp revenue decline

A steep multi‑period revenue decline undermines scale economics and raises concerns about commercial traction or partner revenue continuity. Persistent top-line weakness limits reinvestment capacity, pressures margins, and heightens execution risk over the medium term.

Negative stockholders' equity

Negative equity signals liabilities exceed assets, creating solvency risk and constraining financing options. Over months, this can force dilutive capital raises or asset sales, weaken bargaining power with partners, and limit ability to sustain costly late‑stage trials.

Persistent negative operating cash flow

Ongoing negative operating cash flow means the company relies on external financing to fund operations and trials. Even with recent FCF growth, persistent cash burn reduces strategic flexibility, risks delaying programs if capital markets tighten, and may increase dilution risk.

Adaptimmune Therapeutics Business Overview & Revenue Model

Company Description

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

How the Company Makes Money

Adaptimmune Therapeutics generates revenue primarily through collaborations and partnerships with pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on future sales of therapies developed in partnership. The company may also earn revenue from clinical trial agreements and grants that support its research and development efforts. Additionally, any successful commercialization of its SPEAR T-cell therapies could lead to significant revenue through product sales, particularly if these therapies gain regulatory approval and are adopted widely in clinical settings.

Adaptimmune Therapeutics Financial Statement Overview

Summary

Adaptimmune Therapeutics is facing significant financial challenges, with declining revenues, negative profitability, and a precarious balance sheet. Despite some improvement in free cash flow growth, the company's financial health remains weak, requiring strategic interventions to stabilize and improve its financial position.

Income Statement

Adaptimmune Therapeutics has experienced significant revenue volatility, with a sharp decline in TTM revenue growth of -63.77%. The company maintains a high gross profit margin of 98.06% in TTM, but this is overshadowed by negative net profit margins and EBIT margins, indicating ongoing operational challenges and profitability issues.

Balance Sheet

The balance sheet reveals a concerning financial structure with a negative stockholders' equity in TTM, leading to a negative debt-to-equity ratio. The return on equity is also negative, reflecting substantial losses relative to equity. These factors suggest financial instability and potential solvency risks.

Cash Flow

Cash flow analysis shows a significant free cash flow growth of 73.93% in TTM, but the company still faces negative operating cash flow and free cash flow figures. The operating cash flow to net income ratio is negative, indicating cash flow challenges relative to earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	65.08M	178.03M	60.28M	27.15M	6.15M	3.96M
Gross Profit	61.70M	177.96M	50.42M	-100.58M	-104.94M	-87.61M
EBITDA	-149.75M	-52.66M	-128.20M	-155.59M	-155.68M	-125.81M
Net Income	-169.76M	-70.81M	-113.87M	-165.46M	-158.09M	-130.09M
Balance Sheet
Total Assets	130.63M	245.96M	282.62M	328.92M	469.55M	451.14M
Cash, Cash Equivalents and Short-Term Investments	26.06M	151.60M	146.94M	204.60M	369.58M	368.22M
Total Debt	48.68M	74.21M	25.23M	23.08M	25.47M	23.71M
Total Liabilities	201.59M	234.11M	243.10M	247.04M	263.58M	109.92M
Stockholders Equity	-70.96M	11.85M	39.51M	81.88M	205.96M	341.23M
Cash Flow
Free Cash Flow	-191.71M	-75.93M	-145.76M	-171.51M	1.95M	-56.50M
Operating Cash Flow	-190.03M	-73.21M	-140.88M	-141.77M	10.73M	-53.59M
Investing Cash Flow	1.79M	-58.95M	176.54M	89.14M	75.80M	-278.92M
Financing Cash Flow	1.34M	78.75M	880.00K	12.87M	3.29M	340.05M

Adaptimmune Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.03
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADAPY, the sentiment is Neutral. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.04, and below the 200-day MA of 0.14, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 54.55 is Neutral, neither overbought nor oversold. The STOCH value of 90.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ADAPY.

Adaptimmune Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XLO	49 Neutral	$33.01M	-0.96	-908.28%	―	588.40%	61.76%
SNTI	48 Neutral	$28.39M	-0.32	-394.62%	―	―	78.60%
ADAPY	44 Neutral	$9.28M	-0.05	-1341.37%	―	-53.61%	-93.14%
BCAB	44 Neutral	$22.62M	-0.31	―	―	-100.00%	32.37%